US Patent

US7959946 — Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Formulation · Assigned to Watson Pharmaceuticals Inc · Expires 2026-07-31 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical formulation containing a controlled release component with an antihyperglycemic drug and a thiazolidinedione derivative.

USPTO Abstract

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Drugs covered by this patent

metformin-hydrochloride (METFORMIN HYDROCHLORIDE)

Patent Metadata

Patent number: US7959946
Jurisdiction: US
Classification: Formulation
Expires: 2026-07-31
Drug substance claim: No
Drug product claim: Yes
Assignee: Watson Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.